AR066199A1 - Metodo para reducir la concentracion del peptido amiloide beta - Google Patents

Metodo para reducir la concentracion del peptido amiloide beta

Info

Publication number
AR066199A1
AR066199A1 ARP080101265A ARP080101265A AR066199A1 AR 066199 A1 AR066199 A1 AR 066199A1 AR P080101265 A ARP080101265 A AR P080101265A AR P080101265 A ARP080101265 A AR P080101265A AR 066199 A1 AR066199 A1 AR 066199A1
Authority
AR
Argentina
Prior art keywords
amyloid peptide
beta amyloid
protein component
protein
concentration
Prior art date
Application number
ARP080101265A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR066199A1 publication Critical patent/AR066199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Proteínas de fusion y a su uso en el tratamiento enzimático de pacientes con la enfermedad de Alzheimer. Reivindicacion 1: Una proteína de fusion que tiene la formula M-A, capaz de degradar el péptido amiloide beta en uno o más sitios de escision en dicha secuencia de aminoácidos de péptido amiloide beta, donde M es un componente proteico que prolonga la vida media de la proteína de fusion, y A es un componente proteico que escinde el péptido amiloide beta, donde dicho componente proteico M está conectado covalentemente a la parte del N-término del componente proteico A. Reivindicacion 28: Una composicion farmacéutica capaz de degradar el péptido amiloide beta, que comprende una cantidad farmacéuticamente aceptable de proteína de fusion de acuerdo con cualquiera de las reivindicaciones 1 a 23 conjuntamente con un portador o excipiente farmacéuticamente aceptable.
ARP080101265A 2007-03-28 2008-03-27 Metodo para reducir la concentracion del peptido amiloide beta AR066199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90847107P 2007-03-28 2007-03-28

Publications (1)

Publication Number Publication Date
AR066199A1 true AR066199A1 (es) 2009-08-05

Family

ID=39788753

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101265A AR066199A1 (es) 2007-03-28 2008-03-27 Metodo para reducir la concentracion del peptido amiloide beta

Country Status (12)

Country Link
US (1) US20080242590A1 (es)
EP (1) EP2139525A4 (es)
JP (1) JP2010522559A (es)
CN (1) CN101668545A (es)
AR (1) AR066199A1 (es)
AU (1) AU2008230177B2 (es)
CA (1) CA2681404A1 (es)
CL (1) CL2008000910A1 (es)
PE (1) PE20090225A1 (es)
TW (1) TW200907056A (es)
UY (1) UY30984A1 (es)
WO (1) WO2008118093A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530498A (ja) 2009-06-19 2012-12-06 メディミューン，エルエルシー プロテアーゼバリアント
WO2011161127A1 (en) 2010-06-21 2011-12-29 Medimmune, Llc Protease variants of human neprilysin
WO2011160732A1 (en) 2010-06-21 2011-12-29 Medimmune, Llc. Protease variants of human neprilysin
WO2012145428A2 (en) * 2011-04-21 2012-10-26 Washington University Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid
CN103529182B (zh) * 2012-07-06 2016-03-16 中国科学院上海生命科学研究院 rbo/Efr3a/Efr3b基因或其蛋白在诊断和治疗阿尔茨海默病中的应用
EP2832854A1 (en) * 2013-08-02 2015-02-04 F. Hoffmann-La Roche AG Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin
EP3027280A1 (en) * 2013-08-02 2016-06-08 F. Hoffmann-La Roche AG Therapeutic fusion protein
EP3147668B1 (en) * 2014-05-22 2019-12-11 Shimadzu Corporation Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof
CN109071600A (zh) * 2016-04-14 2018-12-21 道健康生活医药株式会社 淀粉样蛋白球体（aspd）结合抑制肽以及评价和筛选方法
WO2018138709A1 (en) * 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
CN110241128B (zh) * 2018-03-07 2020-10-02 上海大学 一种含有cbd的融合基因、细胞系、液态ecm与应用
CA3107349A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
CA3107352A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
JP2022526671A (ja) 2019-04-11 2022-05-25 エンクリアー セラピーズ， インク． 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
HUP0100813A3 (en) * 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
US20020086405A1 (en) * 2000-09-25 2002-07-04 Inmaculada Silos-Santiago 56638, a novel human neprilysin protease and uses thereof
CA2260376A1 (en) * 1999-02-11 2000-08-11 Universite De Montreal New metalloproteases of the neprilysin family
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
WO2002096460A1 (en) * 2001-05-30 2002-12-05 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
US20050118632A1 (en) * 2003-11-06 2005-06-02 Jian Chen Polynucleotides and polypeptides encoding a novel metalloprotease, Protease-40b
EP1934341A1 (en) * 2005-10-03 2008-06-25 AstraZeneca AB Fusion proteins having a modulated half-life in plasma

Also Published As

Publication number Publication date
UY30984A1 (es) 2008-10-31
TW200907056A (en) 2009-02-16
CA2681404A1 (en) 2008-10-02
CL2008000910A1 (es) 2008-11-21
PE20090225A1 (es) 2009-04-19
AU2008230177B2 (en) 2012-05-10
AU2008230177A1 (en) 2008-10-02
EP2139525A4 (en) 2010-08-18
US20080242590A1 (en) 2008-10-02
JP2010522559A (ja) 2010-07-08
WO2008118093A1 (en) 2008-10-02
CN101668545A (zh) 2010-03-10
EP2139525A1 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
AR066199A1 (es) Metodo para reducir la concentracion del peptido amiloide beta
BRPI0407001A (pt) Método para aumentar a estabilidade de uma proteìna purificada, uso de uma proteìna ligante sìtio-especìfica ativa, método para aumentar a produção de uma proteìna recombinante e composição farmacêutica
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
BRPI0408331B8 (pt) conjugado de proteína, processo para preparação do dito conjugado de proteína, composição farmacêutica e processo para prolongar a meia vida útil in vivo de um polipeptídeo fisiologicamente ativo
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
NO20076239L (no) Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom
AR069135A1 (es) Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide
BRPI0519193A2 (pt) mÉtodo para produzir suspensÕes estÉreis ou liofilisados de complexos peptÍdicos bÁsicos fracamente soléveis, formulaÇÕes farmacÊuticas contendo os mesmos, e aplicaÇço dos mesmos como medicamentos
EA200802396A1 (ru) УЛУЧШЕННЫЕ ДИМЕРЫ sgp130Fc
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
BRPI0411112A (pt) proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga
DK1877435T3 (da) Glucagon-lignende peptid 2 (GLP-2)-analoger
AR053252A1 (es) Antiuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PE20081634A1 (es) Fab ab pegilado
US20130205416A1 (en) Anti-viral agent
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
Gibson et al. Design of peptidyl compounds that affect β-amyloid aggregation: importance of surface tension and context
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
BR112014007675A2 (pt) tratamento de doença articular degenerativa
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal